Abstract
The efficacy of antiplatelet therapy for the secondary prevention of cardiovascular disease after an ischemic event is well established. However, the role for antiplatelet therapy for the primary prevention of cardiovascular disease is more complex because of the interplay of efficacy vs safety in individuals without established cardiovascular disease who have a relatively low, but linear trajectory of cardiovascular risk. Several large randomized trials have investigated the efficacy and safety of antiplatelet therapy (primarily aspirin) for patients without established cardiovascular disease. The pharmacological profile of the most commonly used primary prevention antiplatelet agent, aspirin, has been delineated by randomized clinical trials and showcased in practice guidelines for reducing cardiovascular risk. For this indication, aspirin has been consistently shown to reduce the risk of non-fatal myocardial infarction with little impact on cardiovascular death, but with a consistent increased risk of bleeding. These divergent results have contributed to differences in the recommendations from international practice guidelines and highlight controversy at the forefront of considerations for anti-platelet therapy for primary prevention. However, further studies in specific sub-groups of patients without established cardiovascular disease such as those with Diabetes Mellitus, chronic kidney disease, or the elderly may clarify which patient groups will benefit the most from aspirin treatment for the primary prevention of a cardiovascular event.
Keywords: Aspirin, primary prevention, cardiovascular disease, antiplatelet therapy, review, cardiovascular mortality.
Current Pharmaceutical Design
Title:The Role of Antiplatelet Therapy in Primary Prevention. A Review
Volume: 23 Issue: 9
Author(s): Lauge Ostergaard*, Emil L. Fosbol and Matthew T. Roe
Affiliation:
- Lauge Østergaard, Blegdamsvej 9, 2100 Copenhagen,Denmark
Keywords: Aspirin, primary prevention, cardiovascular disease, antiplatelet therapy, review, cardiovascular mortality.
Abstract: The efficacy of antiplatelet therapy for the secondary prevention of cardiovascular disease after an ischemic event is well established. However, the role for antiplatelet therapy for the primary prevention of cardiovascular disease is more complex because of the interplay of efficacy vs safety in individuals without established cardiovascular disease who have a relatively low, but linear trajectory of cardiovascular risk. Several large randomized trials have investigated the efficacy and safety of antiplatelet therapy (primarily aspirin) for patients without established cardiovascular disease. The pharmacological profile of the most commonly used primary prevention antiplatelet agent, aspirin, has been delineated by randomized clinical trials and showcased in practice guidelines for reducing cardiovascular risk. For this indication, aspirin has been consistently shown to reduce the risk of non-fatal myocardial infarction with little impact on cardiovascular death, but with a consistent increased risk of bleeding. These divergent results have contributed to differences in the recommendations from international practice guidelines and highlight controversy at the forefront of considerations for anti-platelet therapy for primary prevention. However, further studies in specific sub-groups of patients without established cardiovascular disease such as those with Diabetes Mellitus, chronic kidney disease, or the elderly may clarify which patient groups will benefit the most from aspirin treatment for the primary prevention of a cardiovascular event.
Export Options
About this article
Cite this article as:
Ostergaard Lauge*, Fosbol L. Emil and Roe T. Matthew, The Role of Antiplatelet Therapy in Primary Prevention. A Review, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161205115540
DOI https://dx.doi.org/10.2174/1381612822666161205115540 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Current Vascular Pharmacology Probiotics and Oral Health
Current Pharmaceutical Design The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Current Drug Targets Drug Hypersensitivity: Epidemiology and Risk Factors
Current Pharmaceutical Design The Effects of Glucose-Lowering Therapies on Diabetic Kidney Disease
Current Diabetes Reviews Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide
Current Pharmaceutical Biotechnology Reacting to Stress: Radical Cellular Pathways for Novel Drug Development
Current Neurovascular Research Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Withdrawal Notice: Clinical Pathways Optimization from Decision Rules Based on Fusion Stream Mining and Fuzzy Unordered Rule Induction Strategy in Diabetes Treatment
Current Bioinformatics Design of Novel Biphenyl-2-thioxothiazolidin-4-one Derivatives as Potential Protein Tyrosine Phosphatase (PTP)-1B Inhibitors Using Molecular Docking Study
Letters in Drug Design & Discovery Targeting the AMP-Activated Protein Kinase for the Treatment of Type 2 Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Involvement of Uric Acid in the Pathogenesis of Preeclampsia
Current Hypertension Reviews Complex Obesity
Current Pediatric Reviews Five Years Patenting Time Frame Concerning Enzymatic Preparation of Glycosides
Recent Patents on Biotechnology Gene-Gene and Gene-Environment Interplay Represent Specific Susceptibility for Different Types of Ischaemic Stroke and Leukoaraiosis
Current Medicinal Chemistry Model for Gestational Diabetes on Web Based Parameters
Recent Patents on Engineering DNA Vaccines: A Mini Review
Recent Patents on DNA & Gene Sequences